Maravai Lifesciences Holdings (MRVI) Restructuring Costs (2023 - 2026)

Maravai Lifesciences Holdings' Restructuring Costs history runs 4 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Restructuring Costs changed N/A year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $20.7 million, a 1035350.0% increase from a year earlier, with the FY2025 full-year figure at $17.8 million, up 1568.45% from the prior year.
• Restructuring Costs slipped to $2.9 million in Q1 2026 per MRVI's latest filing, from $10.4 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $10.4 million in Q4 2025 and bottomed at -$1.2 million in Q1 2024.
• The 4-year median for Restructuring Costs is $1.4 million (2024), against an average of $3.2 million.
• Across the five-year window, Restructuring Costs plunged 99.91% in 2024 and jumped 184750.0% in 2025, its largest moves.
• Year by year, Restructuring Costs stood at $6.5 million in 2023, then plunged by 99.91% to $6000.0 in 2024, then jumped by 173916.67% to $10.4 million in 2025, then slumped by 72.44% to $2.9 million in 2026.
• Per Business Quant, the three latest MRVI Restructuring Costs figures stand at $2.9 million (Q1 2026), $10.4 million (Q4 2025), and $7.4 million (Q3 2025).